

Disclosures

Personal Commercial (5)

Company Name	Relationship Category	Compensation Level	Topic Area(s)
Self			
Akcea Therapeutics	Research/Research Grants ‡ Spinal stenosis and ATTR amyloidosis - investigator initiated study	Significant (>= \$5,000)	Heart Failure and Cardiomyopathies
Alnylam Pharmaceuticals	Research/Research Grants ‡ Co-investigator on investigator initiated award, PI Hanna Gaggin, MD, Mass General Hospital	Significant (>= \$5,000)	Heart Failure and Cardiomyopathies
Astra Zeneca	Consultant Fees/Honoraria	Modest (< \$5,000)	Heart Failure and Cardiomyopathies
Pfizer, Inc.	Research/Research Grants ‡ Co-investigator on investigator initiated award, PI Ethan Rowin, MD - Tufts Medical Center	Significant (>= \$5,000)	Heart Failure and Cardiomyopathies
Pfizer, Inc.	Research/Research Grants ‡ Training grant for amyloidosis research fellowship	Significant (>= \$5,000)	Heart Failure and Cardiomyopathies

Additional Personal Commercial Disclosures for Education Activities (0)

No disclosures on record

Personal Organizational or Other Non-Commercial (1)

Non-Commercial Entity Name	Relationship Category	Compensation Level	Topic Area(s)
Self			
National Institutes of Health	Research/Research Grants ‡ Multi-PI of R01HL139671-01A1	Significant (>= \$5,000)	Heart Failure and Cardiomyopathies

Clinical Trial Enroller (0)

No disclosures on record

Institutional Financial Decision-Making Role (1)

Funding Source	Institutional Compensation Level
National Institutes of Health	Significant (>= \$5,000)

Expert Witness Testimony (0)

No disclosures on record

‡ Commercial Funding Source | ‡ Trial Name

Agreement

Certified Education Attestation | Signed on 9/1/2023

URL for full agreement: <http://disclosures.acc.org/Public/Definition/CertifiedEducationAttestationAgreement>

Confidentiality, Disclosure and Assignment Agreement | Signed on 9/1/2023

URL for full agreement: <http://disclosures.acc.org/Public/Definition/ConfidentialityDisclosureandAssignmentAgreement>

Embargo | Signed on 9/1/2023

URL for full agreement: <http://disclosures.acc.org/Public/Definition/EmbargoAgreement>

On-Going Obligation Agreement | Signed on 9/1/2023

ACC is committed to ensuring balance, independence, objectivity, and scientific rigor in their governance, programmatic, educational, chapter, and other activities. Fulfilling this commitment depends on member and public confidence in the College's integrity and objectivity. The College recognizes that the activities of College members in their practice, research, and other volunteer and private endeavors could lead to the development of conflicts of interest. Therefore, the College has established a Disclosure Policy and conflict of interest management process as appropriate. All members involved in College governance, including all committees and task forces, programmatic, certified educational, chapter, and other activities must provide complete, timely, accurate, and signed disclosure statements. Compliance with this process is mandatory for participation in College activities.